IPO News Archive

Drug developer Merrimack postpones IPO

2/1/12


Merrimack Pharmaceuticals, which uses its Network Biology system to discover and develop cancer treatments, postponed its IPO on Wednesday due to poor market conditions. The Cambridge, MA-based company was founded in 1993 and currently has five candidates in clinical programs. J.P. Morgan had been selected to lead manage the IPO.
Keywords/Tickers: MACK
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest